A 35-year-old female with moderate-to-severe atopic dermatitis has been treated with tralokinumab 300 mg every 2 weeks (Q2W) for 16 weeks. She achieved clear skin (IGA 0) and reports a worst daily pruritus Numeric Rating Scale (NRS) score of 2 consistently over the past 4 weeks. She is interested in reducing her injection frequency due to work-related travel and inconvenience.

Based on the study findings, which of the following is the most appropriate recommendation regarding her tralokinumab dosing regimen?

A 42-year-old male with moderate-to-severe atopic dermatitis was switched from tralokinumab 300 mg every 2 weeks (Q2W) to every 4 weeks (Q4W) after achieving stable disease control. At week 40, he experiences a relapse with worsening skin lesions and pruritus. He returns to the clinic seeking advice on managing this relapse.

What is the best evidence-based recommendation for managing his tralokinumab therapy following relapse on the Q4W regimen?

A 28-year-old female with moderate-to-severe atopic dermatitis has been on tralokinumab 300 mg every 4 weeks (Q4W) for maintenance after initial Q2W therapy. She is concerned about the development of anti-drug antibodies and potential loss of efficacy or adverse effects with the extended dosing interval.

What information can the pharmacist provide regarding immunogenicity and safety of tralokinumab when dosing frequency is reduced to every 4 weeks?